Addex regains global rights to GABAB PAM assets from Indivior

Bitget2026/09/25 05:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Addex Therapeutics regained full global rights to its GABAB positive allosteric modulator portfolio from Indivior on Sept. 25, 2026.
Transaction returns a development candidate Indivior had selected, giving Addex full ownership and control of future development.
Rights reversion followed Indivior’s R&D rationalization tied to the planned merger of its parent with Supernus Pharmaceuticals.
Addex plans to weigh options, including new partnering discussions or further internal development of the substance use disorder candidate.
Returned asset expands Addex’s GABAB PAM pipeline alongside its wholly owned chronic cough program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250100OMX_____CNEWS_EN_GNW1001274520_en) on September 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Addex regains global rights to GABAB PAM assets from Indivior

You may also like

Crypto prices